Keytruda covers 22 cancers but out of reach for most Indian patients

Pembrolizumab (Keytruda) is now approved across 22 cancer types and remains one of the world’s top-selling oncology drugs, but access in India is severely constrained by patent protection until June 2028 and high pricing. A standard six-month course costs roughly Rs 10.1 lakh per month, or more than Rs 1.2 crore annually, putting treatment out of reach for most patients in a market where less than 3% can access new immunotherapies. The article highlights potential post-2028 biosimilar price relief, but near-term access remains limited.

Analysis

The investable takeaway is not a near-term demand shock, but a long-duration pricing moat for the incumbent. In markets like India, patent protection plus biologic complexity can keep effective exclusivity far longer than headline expiry implies, especially where local biosimilar capacity still needs expensive comparability data and manufacturing scale. That means the usual “patent cliff = rapid price collapse” template is likely too optimistic here; the more realistic path is a staggered erosion of pricing power over multiple years, not a clean step-down.

The second-order winner is the broader oncology ecosystem that can serve patients who are priced out of branded immunotherapy: domestic diagnostics, radiation, surgery, and lower-cost chemo combinations should see incremental utilization. For multinational peers, the issue is not just India revenue—it's the signaling effect on emerging markets pricing architecture. If payer resistance hardens in India, it becomes harder for other large EMs to justify premium biologic reimbursement, creating a slower but wider drag on global growth assumptions for premium oncology franchises.

The key catalyst window is 2027-2028, when policy, litigation, and biosimilar filings start to matter materially. Before then, the main risk to the thesis is a policy intervention such as accelerated biosimilar approval, compulsory licensing pressure, or an institutional purchaser forcing a negotiated discount. Over the next 12-24 months, any visible movement from CDSCO on streamlined biosimilar pathways would matter more for sentiment than for actual revenue, but it would mark the start of a real margin compression regime for the originator.

Contrarian view: the market may be underestimating how little of the global Keytruda opportunity depends on India today, so the near-term earnings impact on the parent is probably immaterial. The more relevant trade is on Indian healthcare affordability and biosimilar competition, where the path to monetization is delayed but the eventual pricing inflection could be sharp once local supply scales. In other words, this is less a short the innovator story than a long-duration optionality trade on biosimilars and access-driven treatment expansion.

Key Decisions for Investors

• Avoid initiating a short in MRK on this headline alone; the India access issue is a multi-year EM pricing problem, not a near-term global earnings risk. Reassess only if there is formal compulsory licensing or accelerated biosimilar approval within the next 6-12 months.
• Build a watchlist long in Indian biosimilar / biologics manufacturing exposure via larger platform names with oncology capability (e.g., DRREDDY, CIPLA, BIOCON) for 12-24 months out; best risk/reward is on any regulatory fast-tracking that compresses approval timelines and expands addressable biosimilar margins.
• Pair trade idea: long Indian healthcare delivery/diagnostics beneficiaries vs short premium imported pharma exposure in India; the spread should widen if affordability constraints keep pushing patients toward lower-cost, non-immunotherapy pathways over the next 4-8 quarters.
• For public-market hedging, consider a small long-dated call spread on a diversified biosimilar basket rather than single-name exposure; optionality is highest into the 2027-2028 patent window, with limited premium bleed if policy change remains slow.
• Set a policy catalyst alert on CDSCO biosimilar guideline changes and any compulsory licensing rhetoric; if either moves from theory to process, expect a 20-30% re-rating in domestic biosimilar names over a 3-6 month horizon.